Skip to content

CDR

Upsher-Smith sells AmLactin to Sandoz

Upsher-Smith sells AmLactin to Sandoz

Upsher-Smith Laboratories Inc. has entered an agreement to sell its AmLactin skin care brand to Sandoz Inc. Financial terms of the deal weren’t disclosed. Upsher-Smith said the move is part of its strategy of focusing on generic drugs and novel ­therapies.

2016 NACDS Foundation Dinner in photos

2016 NACDS Foundation Dinner in photos

The 2016 NACDS Foundation Dinner, part of NACDS Week in New York, raised $1.94 million for evidence-based research, pharmacy education and philanthropic initiatives to improve patient outcomes and advance population health. Dr.

Omnicell wraps up Ateb acquisition

Omnicell wraps up Ateb acquisition

Omnicell Inc. has closed its $41 million deal to acquire pharmacy patient care and medication synchronization specialist Ateb Inc. Omnicell and Ateb announced the agreement late last month.

Merlo: Integrated care sets CVS Health apart

Merlo: Integrated care sets CVS Health apart

CVS Health’s integrated pharmacy care model makes it a “partner of choice” in the health care arena, president and chief executive officer Larry Merlo said at the company’s annual Analyst Day event in Manhattan.

NACDS hails rule relaxing access to pharmacy rewards

NACDS hails rule relaxing access to pharmacy rewards

The Department of Health and Human Services (HHS) is giving pharmacies more flexibility to extend their reward and loyalty programs to beneficiaries in government programs such as Medicare and Medicaid, according to the National Association of Chain Drug Stores.

Branded drug prices jumped last year, AARP says

Branded drug prices jumped last year, AARP says

Retail prices for 268 branded prescription drugs widely used by older Americans climbed by an average of 15.5% in 2015, according to a new report by the AARP Public Policy Institute. AARP said Wednesday that the gain in branded drug prices was nearly 130 times faster than the 0.

McKesson cleared to acquire Rexall

McKesson cleared to acquire Rexall

McKesson Corp. has been given the green light from the Competition Bureau of Canada to finalize its $2.2 billion acquisition of drug chain Rexall Health.